Asset Management
Compare Stocks
5 / 10Stock Comparison
INV vs XOMA vs GCBC vs NTLA vs ACIC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Banks - Regional
Biotechnology
Insurance - Property & Casualty
INV vs XOMA vs GCBC vs NTLA vs ACIC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Asset Management | Biotechnology | Banks - Regional | Biotechnology | Insurance - Property & Casualty |
| Market Cap | $349M | $490M | $408M | $1.62B | $525M |
| Revenue (TTM) | $1M | $52M | $133M | $68M | $335M |
| Net Income (TTM) | $-317M | $29M | $37M | $-413M | $107M |
| Gross Margin | -271.2% | 94.3% | 55.7% | -25.6% | 63.8% |
| Operating Margin | -63.2% | 21.8% | 26.1% | -6.5% | 42.6% |
| Forward P/E | — | 36.7x | 13.1x | — | 7.3x |
| Total Debt | $28M | $132M | $128M | $93M | $152M |
| Cash & Equiv. | $11M | $83M | $185M | $155M | $199M |
INV vs XOMA vs GCBC vs NTLA vs ACIC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Innventure, Inc. (INV) | 100 | 62.1 | -37.9% |
| XOMA Royalty Corp. (XOMA) | 100 | 201.3 | +101.3% |
| Greene County Banco… (GCBC) | 100 | 142.0 | +42.0% |
| Intellia Therapeuti… (NTLA) | 100 | 11.9 | -88.1% |
| American Coastal In… (ACIC) | 100 | 262.7 | +162.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INV vs XOMA vs GCBC vs NTLA vs ACIC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, INV doesn't own a clear edge in any measured category.
XOMA carries the broadest edge in this set and is the clearest fit for growth exposure and defensive.
- Rev growth 83.1%, EPS growth 188.5%, 3Y rev CAGR 105.3%
- Beta 1.21, yield 0.7%, current ratio 3.37x
- 83.1% revenue growth vs INV's 9.2%
- 56.4% margin vs INV's -64.1%
GCBC ranks third and is worth considering specifically for income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 0.86, yield 1.1%
- 198.9% 10Y total return vs ACIC's -22.2%
- PEG 1.22 vs XOMA's 2.75
- 1.1% yield, 2-year raise streak, vs INV's 0.2%, (2 stocks pay no dividend)
NTLA is the clearest fit if your priority is momentum.
- +88.1% vs ACIC's -0.3%
ACIC is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.39, Low D/E 48.0%, current ratio 1.22x
- Better valuation composite
- Beta 0.39 vs INV's 2.63
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 83.1% revenue growth vs INV's 9.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 56.4% margin vs INV's -64.1% | |
| Stability / Safety | Beta 0.39 vs INV's 2.63 | |
| Dividends | 1.1% yield, 2-year raise streak, vs INV's 0.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +88.1% vs ACIC's -0.3% | |
| Efficiency (ROA) | 12.1% ROA vs INV's -47.4%, ROIC 7.4% vs -14.8% |
INV vs XOMA vs GCBC vs NTLA vs ACIC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
INV vs XOMA vs GCBC vs NTLA vs ACIC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACIC leads in 4 of 6 categories
GCBC leads 1 • INV leads 0 • XOMA leads 0 • NTLA leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ACIC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACIC is the larger business by revenue, generating $335M annually — 274.7x INV's $1M. XOMA is the more profitable business, keeping 56.4% of every revenue dollar as net income compared to INV's -64.1%. On growth, NTLA holds the edge at +78.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $52M | $133M | $68M | $335M |
| EBITDAEarnings before interest/tax | -$451M | $14M | $42M | -$431M | $154M |
| Net IncomeAfter-tax profit | -$317M | $29M | $37M | -$413M | $107M |
| Free Cash FlowCash after capex | -$87M | $3M | $33M | -$396M | $71M |
| Gross MarginGross profit ÷ Revenue | -2.7% | +94.3% | +55.7% | -25.6% | +63.8% |
| Operating MarginEBIT ÷ Revenue | -63.2% | +21.8% | +26.1% | -6.5% | +42.6% |
| Net MarginNet income ÷ Revenue | -64.1% | +56.4% | +23.4% | -6.1% | +31.9% |
| FCF MarginFCF ÷ Revenue | -40.2% | +5.4% | +20.5% | -5.8% | +21.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +57.9% | — | +78.8% | +9.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.3% | +157.8% | +36.4% | +34.6% | +4.3% |
Valuation Metrics
ACIC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 5.0x trailing earnings, ACIC trades at a 82% valuation discount to XOMA's 28.3x P/E. Adjusting for growth (PEG ratio), GCBC offers better value at 1.22x vs XOMA's 2.12x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $349M | $490M | $408M | $1.6B | $525M |
| Enterprise ValueMkt cap + debt − cash | $366M | $538M | $352M | $1.6B | $478M |
| Trailing P/EPrice ÷ TTM EPS | -3.55x | 28.28x | 13.11x | -3.60x | 5.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 36.74x | — | — | 7.33x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.12x | 1.22x | — | — |
| EV / EBITDAEnterprise value multiple | — | 37.50x | 9.85x | — | 2.93x |
| Price / SalesMarket cap ÷ Revenue | 286.17x | 9.39x | 3.07x | 23.93x | 1.56x |
| Price / BookPrice ÷ Book value/share | 0.36x | 8.85x | 1.71x | 2.21x | 1.70x |
| Price / FCFMarket cap ÷ FCF | — | 170.55x | 14.97x | — | 7.40x |
Profitability & Efficiency
ACIC leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ACIC delivers a 35.7% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-59 for INV. INV carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.57x. On the Piotroski fundamental quality scale (0–9), GCBC scores 7/9 vs INV's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -58.9% | +31.9% | +15.0% | -56.6% | +35.7% |
| ROA (TTM)Return on assets | -47.4% | +12.1% | +1.2% | -45.2% | +9.0% |
| ROICReturn on invested capital | -14.8% | +7.4% | +6.7% | -44.0% | +41.0% |
| ROCEReturn on capital employed | -18.1% | +5.2% | +10.7% | -48.5% | +26.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 7 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.04x | 1.57x | 0.54x | 0.14x | 0.48x |
| Net DebtTotal debt minus cash | $17M | $49M | -$56M | -$62M | -$46M |
| Cash & Equiv.Liquid assets | $11M | $83M | $185M | $155M | $199M |
| Total DebtShort + long-term debt | $28M | $132M | $128M | $93M | $152M |
| Interest CoverageEBIT ÷ Interest expense | -57.53x | 2.90x | 0.74x | — | 14.20x |
Total Returns (Dividends Reinvested)
ACIC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACIC five years ago would be worth $20,705 today (with dividends reinvested), compared to $2,024 for NTLA. Over the past 12 months, NTLA leads with a +88.1% total return vs ACIC's -0.3%. The 3-year compound annual growth rate (CAGR) favors ACIC at 37.3% vs NTLA's -31.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +38.6% | +47.5% | +10.7% | +48.9% | +1.9% |
| 1-Year ReturnPast 12 months | +59.2% | +68.7% | +10.9% | +88.1% | -0.3% |
| 3-Year ReturnCumulative with dividends | -40.0% | +126.1% | +37.1% | -68.3% | +159.1% |
| 5-Year ReturnCumulative with dividends | -37.9% | +30.0% | +97.6% | -79.8% | +107.0% |
| 10-Year ReturnCumulative with dividends | -37.9% | +186.7% | +198.9% | -42.9% | -22.2% |
| CAGR (3Y)Annualised 3-year return | -15.7% | +31.3% | +11.1% | -31.8% | +37.3% |
Risk & Volatility
Evenly matched — XOMA and ACIC each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACIC is the less volatile stock with a 0.39 beta — it tends to amplify market swings less than INV's 2.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XOMA currently trades 96.4% from its 52-week high vs NTLA's 48.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.63x | 1.21x | 0.86x | 2.37x | 0.39x |
| 52-Week HighHighest price in past year | $7.45 | $42.81 | $26.04 | $28.25 | $13.06 |
| 52-Week LowLowest price in past year | $2.36 | $22.29 | $21.16 | $6.83 | $9.79 |
| % of 52W HighCurrent price vs 52-week peak | +83.4% | +96.4% | +92.1% | +48.5% | +83.1% |
| RSI (14)Momentum oscillator 0–100 | 66.0 | 71.1 | 55.9 | 50.4 | 31.0 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 242K | 12K | 5.3M | 188K |
Analyst Outlook
GCBC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: XOMA as "Buy", NTLA as "Buy", ACIC as "Hold". Consensus price targets imply 52.3% upside for NTLA (target: $21) vs -82.5% for ACIC (target: $2). For income investors, GCBC offers the higher dividend yield at 1.10% vs INV's 0.24%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | Buy | Hold |
| Price TargetConsensus 12-month target | $8.00 | $53.75 | — | $20.88 | $1.90 |
| # AnalystsCovering analysts | — | 10 | — | 39 | 5 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | +0.7% | +1.1% | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 2 | — | 1 |
| Dividend / ShareAnnual DPS | $0.01 | $0.30 | $0.26 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.3% | 0.0% | 0.0% | 0.0% |
ACIC leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). GCBC leads in 1 (Analyst Outlook). 1 tied.
INV vs XOMA vs GCBC vs NTLA vs ACIC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INV or XOMA or GCBC or NTLA or ACIC a better buy right now?
For growth investors, XOMA Royalty Corp.
(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus 9. 2% for Innventure, Inc. (INV). American Coastal Insurance Corporation (ACIC) offers the better valuation at 5. 0x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INV or XOMA or GCBC or NTLA or ACIC?
On trailing P/E, American Coastal Insurance Corporation (ACIC) is the cheapest at 5.
0x versus XOMA Royalty Corp. at 28. 3x. On forward P/E, American Coastal Insurance Corporation is actually cheaper at 7. 3x.
03Which is the better long-term investment — INV or XOMA or GCBC or NTLA or ACIC?
Over the past 5 years, American Coastal Insurance Corporation (ACIC) delivered a total return of +107.
0%, compared to -79. 8% for Intellia Therapeutics, Inc. (NTLA). Over 10 years, the gap is even starker: GCBC returned +198. 9% versus NTLA's -42. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INV or XOMA or GCBC or NTLA or ACIC?
By beta (market sensitivity over 5 years), American Coastal Insurance Corporation (ACIC) is the lower-risk stock at 0.
39β versus Innventure, Inc. 's 2. 63β — meaning INV is approximately 572% more volatile than ACIC relative to the S&P 500. On balance sheet safety, Innventure, Inc. (INV) carries a lower debt/equity ratio of 4% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — INV or XOMA or GCBC or NTLA or ACIC?
By revenue growth (latest reported year), XOMA Royalty Corp.
(XOMA) is pulling ahead at 83. 1% versus 9. 2% for Innventure, Inc. (INV). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -143. 1% for Innventure, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INV or XOMA or GCBC or NTLA or ACIC?
XOMA Royalty Corp.
(XOMA) is the more profitable company, earning 60. 8% net margin versus -64. 1% for Innventure, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACIC leads at 42. 6% versus -63. 2% for INV. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INV or XOMA or GCBC or NTLA or ACIC more undervalued right now?
On forward earnings alone, American Coastal Insurance Corporation (ACIC) trades at 7.
3x forward P/E versus 36. 7x for XOMA Royalty Corp. — 29. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTLA: 52. 3% to $20. 88.
08Which pays a better dividend — INV or XOMA or GCBC or NTLA or ACIC?
In this comparison, GCBC (1.
1% yield), XOMA (0. 7% yield), INV (0. 2% yield) pay a dividend. NTLA, ACIC do not pay a meaningful dividend and should not be held primarily for income.
09Is INV or XOMA or GCBC or NTLA or ACIC better for a retirement portfolio?
For long-horizon retirement investors, Greene County Bancorp, Inc.
(GCBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), 1. 1% yield, +198. 9% 10Y return). Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GCBC: +198. 9%, NTLA: -42. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INV and XOMA and GCBC and NTLA and ACIC?
These companies operate in different sectors (INV (Financial Services) and XOMA (Healthcare) and GCBC (Financial Services) and NTLA (Healthcare) and ACIC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INV is a small-cap quality compounder stock; XOMA is a small-cap high-growth stock; GCBC is a small-cap deep-value stock; NTLA is a small-cap high-growth stock; ACIC is a small-cap deep-value stock. XOMA, GCBC pay a dividend while INV, NTLA, ACIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.